National Cancer Institute (NCI)

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).

3,257 total trials 326 currently recruiting 2051 completed early-phase tilt top decile by trial count

National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.

National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.

Top-decile sponsor footprint

National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

3,257 total, page 11 of 66

ACTIVE NOT RECRUITING Phase 2

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

NCT03598257
ACTIVE NOT RECRUITING Phase 2

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

NCT03595124
ACTIVE NOT RECRUITING Phase 2

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

NCT03038672
ACTIVE NOT RECRUITING Phase 2

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

NCT03600701
ACTIVE NOT RECRUITING Phase 1

Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

NCT03598244
ACTIVE NOT RECRUITING Phase 3

Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial

NCT03712605
ACTIVE NOT RECRUITING Phase 2

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

NCT03698994
ACTIVE NOT RECRUITING Phase 2

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

NCT03581292
ACTIVE NOT RECRUITING Phase 1

Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery

NCT03317405
ACTIVE NOT RECRUITING Phase 3

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

NCT03375320
ACTIVE NOT RECRUITING Phase 2

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

NCT06400238
ACTIVE NOT RECRUITING Phase 2

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03587311
ACTIVE NOT RECRUITING Phase 2

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

NCT06360588
ACTIVE NOT RECRUITING Phase 1

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

NCT03126630
ACTIVE NOT RECRUITING Phase 2

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

NCT03660826
ACTIVE NOT RECRUITING Phase 2

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

NCT03289910
ACTIVE NOT RECRUITING Phase 1

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

NCT03218826
ACTIVE NOT RECRUITING Phase 1

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

NCT03321643
ACTIVE NOT RECRUITING Phase 1

T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma

NCT03602612
ACTIVE NOT RECRUITING Phase 2

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

NCT03190915
ACTIVE NOT RECRUITING Phase 2

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

NCT03663933
ACTIVE NOT RECRUITING Phase 2

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

NCT06308822
ACTIVE NOT RECRUITING Phase 1

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

NCT03502733
ACTIVE NOT RECRUITING Phase 1

Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis

NCT03278925
ACTIVE NOT RECRUITING Phase 2

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

NCT03237780
ACTIVE NOT RECRUITING Phase 1

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

NCT03228537
ACTIVE NOT RECRUITING Phase 3

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

NCT03233711
ACTIVE NOT RECRUITING Phase 2

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)

NCT06351371
ACTIVE NOT RECRUITING Phase 2

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

NCT02971501
ACTIVE NOT RECRUITING Phase 2

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

NCT05490771
ACTIVE NOT RECRUITING Phase 2

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

NCT03304639
ACTIVE NOT RECRUITING Phase 2

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

NCT03210714
ACTIVE NOT RECRUITING Phase 2

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

NCT02965716
ACTIVE NOT RECRUITING Phase 1

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

NCT03030378
ACTIVE NOT RECRUITING Phase 2

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

NCT03213652
ACTIVE NOT RECRUITING Phase 2

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

NCT03367741
ACTIVE NOT RECRUITING Phase 1

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

NCT03220022
ACTIVE NOT RECRUITING Phase 2

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

NCT06385483
ACTIVE NOT RECRUITING Phase 1

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

NCT03041688
ACTIVE NOT RECRUITING Phase 2

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

NCT03269669
ACTIVE NOT RECRUITING Phase 3

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

NCT02997228
ACTIVE NOT RECRUITING Phase 2

Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma

NCT02965703
ACTIVE NOT RECRUITING Phase 1

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer

NCT03300817
ACTIVE NOT RECRUITING Phase 2

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

NCT02974621
ACTIVE NOT RECRUITING Phase 3

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

NCT03244384
ACTIVE NOT RECRUITING Phase 1

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

NCT02879695
ACTIVE NOT RECRUITING Phase 3

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

NCT02912559
ACTIVE NOT RECRUITING Phase 2

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

NCT02978625
ACTIVE NOT RECRUITING Phase 1

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT02890329
ACTIVE NOT RECRUITING Phase 2

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

NCT03047213
← Previous Page 11 of 66 Next →

Phase Distribution

PhaseTrial count
Phase 1 1199
Phase 2 1429
Phase 3 193

Therapeutic Areas

Advanced Malignant Solid Neoplasm 67
Refractory Malignant Solid Neoplasm 45
Metastatic Malignant Solid Neoplasm 38
Refractory Multiple Myeloma 35
Prostate Cancer 34
Refractory Lymphoma 33
Advanced Lymphoma 33
Acute Myeloid Leukemia 28
Unspecified Adult Solid Tumor, Protocol Specific 26
Breast Cancer 23

What is open in the National Cancer Institute (NCI) pipeline

326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).

Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).

Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Related

Compare saved trials side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.